Canada Markets closed

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.37+0.11 (+1.76%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close6.26
Open6.21
Bid6.25 x 800
Ask6.30 x 900
Day's Range6.16 - 6.37
52 Week Range5.22 - 17.00
Volume156,853
Avg. Volume285,123
Market Cap161.781M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th

    DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the Cantor Fitzgerald Global Healthcare Conference being held virtually between September 27-30, 2021. Presentation Details:Date: Wednesday, September 29, 2021Time: 9:20 AM ET / 6:20 AM PTWebcast:

  • GlobeNewswire

    Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Heat Biologics' presentation will be available on-demand to registered attendees vi

  • GlobeNewswire

    Heat Biologics to Provide Corporate Update

    Conference call scheduled for September 2nd at 11:00 AM ETDURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company’s activities. The conference call may be accessed by dialing 844-602-0380 for U